Both dMMR and MSI-H have been demonstrated as effective predictors of immunotherapy response (10, 11), and have been approved by the United States Food and Drug Administration as biomarkers for the treatment of solid tumors with immune checkpoint inhibitors targeting programmed death 1 (PD-1), regardless of tumor origin (12). Here, PDCD1 is linked to neoplasm.